HC Wainwright Brokers Reduce Earnings Estimates for AQST

Aquestive Therapeutics, Inc. (NASDAQ:AQST) – Analysts at HC Wainwright dropped their Q2 2025 EPS estimates for shares of Aquestive Therapeutics in a report released on Wednesday, November 6th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of ($0.15) for the quarter, down from their prior estimate of ($0.14). HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Aquestive Therapeutics’ current full-year earnings is ($0.48) per share. HC Wainwright also issued estimates for Aquestive Therapeutics’ FY2025 earnings at ($0.59) EPS.

Several other brokerages have also commented on AQST. Leerink Partners lifted their price target on shares of Aquestive Therapeutics from $12.00 to $13.00 and gave the stock an “outperform” rating in a research note on Friday, October 25th. JMP Securities reiterated a “market outperform” rating and set a $9.00 price target on shares of Aquestive Therapeutics in a research note on Tuesday, October 8th. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $9.80.

Aquestive Therapeutics Price Performance

Shares of NASDAQ:AQST opened at $5.46 on Friday. The company’s fifty day moving average price is $4.94 and its 200 day moving average price is $3.84. Aquestive Therapeutics has a 12 month low of $1.55 and a 12 month high of $6.23. The firm has a market capitalization of $497.84 million, a P/E ratio of -12.13 and a beta of 2.82.

Aquestive Therapeutics (NASDAQ:AQST) last announced its quarterly earnings data on Monday, November 4th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). The firm had revenue of $13.54 million for the quarter, compared to analyst estimates of $12.69 million. During the same quarter last year, the firm earned ($0.03) EPS.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Victory Capital Management Inc. purchased a new stake in shares of Aquestive Therapeutics in the second quarter valued at about $27,000. nVerses Capital LLC purchased a new stake in shares of Aquestive Therapeutics in the third quarter valued at about $28,000. SG Americas Securities LLC purchased a new stake in shares of Aquestive Therapeutics in the first quarter valued at about $54,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Aquestive Therapeutics in the second quarter valued at about $76,000. Finally, Financial Advocates Investment Management boosted its holdings in shares of Aquestive Therapeutics by 70.0% in the second quarter. Financial Advocates Investment Management now owns 34,000 shares of the company’s stock valued at $88,000 after acquiring an additional 14,000 shares in the last quarter. 32.45% of the stock is currently owned by institutional investors and hedge funds.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.